Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
Trials of acyclovir for herpes simplex virus 2 infection in herpes simplex virus 2/HIV-1 coinfected patients not on antiretroviral therapy demonstrated a decrease in herpes simplex virus 2 and HIV-1 replication. Recent studies indicated that acyclovir has direct anti-HIV-1 activity and can select for the HIV-1 V75I reverse transcriptase variant in vitro. We show that the V75I variant has decreased sensitivity to some nucleoside analogs but an increased sensitivity to zidovudine, results that may guide selection of highly active antiretroviral therapy regimens in patients harboring this variant.
McMahon
Moira A
MA
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, MD, USA.
Siliciano
Janet D
JD
Kohli
Rahul M
RM
Siliciano
Robert F
RF
D000212:Acyclovir / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000235:genetics; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006558:Herpes Genitalis / Q000188:drug therapy / Q000235:genetics*; D018258:Herpesvirus 2, Human / Q000235:genetics*; D006801:Humans; D009154:Mutation; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D015215:Zidovudine; C413685:entecavir; D006147:Guanine; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D000212:Acyclovir